NCT00246259View on ClinicalTrials.gov

A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis

PHASE4CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
SchizophreniaSchizoaffective DisorderSchizophreniform DisorderPsychotic Disorders
Interventions
DRUG

Risperidone long-acting injection (LAI)

Risperidone LAI 25 mg, 37.5 mg or 50 mg intramuscular injection will be administered every 2 weeks as per Investigator's discretion.

DRUG

Oral Antipsychotic

Oral antipsychotic (new or current treatment) will be administered in which daily dose range permitted will be risperidone 6 mg; olanzapine 20 mg; quetiapine 800 mg.

Trial Locations (11)

Unknown

Calgary

Edmonton

Victoria

Dartmouth

Greater Sudbury

Kingston

London

Markham

Montreal

Québec

Verdun

All Listed Sponsors
lead

Janssen-Ortho Inc., Canada

INDUSTRY

NCT00246259 - A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis | Biotech Hunter | Biotech Hunter